Home Cart Sign in  
Chemical Structure| 187227-45-8 Chemical Structure| 187227-45-8

Structure of Oseltamivir acid
CAS No.: 187227-45-8

Chemical Structure| 187227-45-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Oseltamivir acid (GS 4071), the active metabolite of Oseltamivir phosphate, is an orally bioavailable, potent, and selective inhibitor of influenza virus neuraminidase with an IC50 of 2 nM, active against both influenza A and B viruses.

Synonyms: Ro 64-0802; Oseltamivir carboxylate; GS 4071

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Oseltamivir acid

CAS No. :187227-45-8
Formula : C14H24N2O4
M.W : 284.35
SMILES Code : CCC(O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O)CC
Synonyms :
Ro 64-0802; Oseltamivir carboxylate; GS 4071
MDL No. :MFCD00953940

Safety of Oseltamivir acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
PBMCs 0.1 μM 24 hours To evaluate the effect of oseltamivir on the killing capacity of PBMCs against A. fumigatus, results showed that oseltamivir-treated PBMCs had decreased killing capacity PMC8149467
neutrophils 0.1 μM 24 hours To evaluate the effect of oseltamivir on the killing capacity of neutrophils against A. fumigatus, results showed that oseltamivir-treated neutrophils had unaffected killing capacity PMC8149467
human neutrophils 100 μM 90 minutes To evaluate the inhibitory effect of Oseltamivir on LPS-induced sialic acid shedding and cell activation in neutrophils, results showed that Oseltamivir significantly inhibited LPS-induced sialic acid shedding and cell activation. PMC9877938
human monocytes 100 μM 90 minutes To evaluate the inhibitory effect of Oseltamivir on LPS-induced sialic acid shedding and cell activation in monocytes, results showed that Oseltamivir significantly inhibited LPS-induced sialic acid shedding and cell activation. PMC9877938
PBMCs 0.2 U/mL 24 hours NA-treated PBMCs produced more TNF-α and IL-1β upon stimulation PMC8149467
Neutrophils 0.2 U/mL 24 hours NA-treated Neutrophils produced more IL-8 upon stimulation PMC8149467

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Immunocompetent mice Oral 2 mg/kg Every two weeks for 5 weeks To evaluate the effect of oseltamivir on pulmonary A. fumigatus infection in mice, results showed that oseltamivir-treated mice had significantly higher fungal burden in the lungs PMC8149467
mice E. coli and K. pneumoniae-induced sepsis model oral Lopinavir/r (133/33.3 mg/kg/day) with zidovudine + lamivudine (100 + 50 mg/kg/day) once daily, starting from gestational day 0.5 until sacrifice To evaluate the effect of Oseltamivir on the survival rate of septic mice, results showed that Oseltamivir significantly improved the survival rate of septic mice and reduced lung neutrophil infiltration and tissue damage. PMC9877938
Ferrets H1N1/2009 influenza virus infection model Intranasal inoculation 10 mg/kg Twice daily for 5 days Studied the transmissibility of Oseltamivir-resistant H1N1/2009 virus in ferrets, finding that the resistant virus was less efficiently transmitted via respiratory droplets but retained efficient transmission via direct contact. PMC2912389
C57BL/6 mice Immunocompetent mice Oral 60, 30, or 15 mg/kg Once daily for 14-21 days Oseltamivir-treated mice had a significantly higher fungal burden in the lungs PMC8149467
mice E. coli-induced peritonitis model oral 12 µM Single dose Oseltamivir significantly improved survival rates in E. coli-induced peritonitis mice, reduced neutrophil infiltration, and improved infection control PMC9877938
ferrets pandemic H1N1/2009 influenza virus model intranasal inoculation 10 mg/kg Twice daily for 5 days To evaluate the transmissibility and fitness of Oseltamivir-resistant virus in ferrets. The results showed that the Oseltamivir-resistant virus was less efficiently transmitted via respiratory droplets but retained efficient transmission via direct contact. PMC2912389

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.52mL

0.70mL

0.35mL

17.58mL

3.52mL

1.76mL

35.17mL

7.03mL

3.52mL

References

 

Historical Records

Categories